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Objectives 
• Understand the impact of HF  
• Understand current approach to diagnosis, 
management, and optimal care 
• Understand current guidelines and 
recommendations 
• Understand goals of therapy and current 
treatments 
HF Statistics 
• Prevalence: 6.6 million Americans (2010) 
• Incidence: >700,000 new cases/year 
• Responsible factors 
– older population  
– 10/1000 in those >65y/o 
– improved cardiac care 
• community defibrillators 
• coronary interventions, surgery 
AHA Heart Disease, 2010 
HF Mortality 
• Causes or contributes to ~300,000 deaths/yr 
(USA)  
– Compared to 40,000 breast cancer 
• In 2008, 1 in 9 death certificates mentioned 
HF 
• 20% die in first year of diagnosis 
– 50% by 5 years  
– 80% by 10 years 
 
 
 
HF Cost 
• Most common cause of 
hospitalization in elderly 
• >1 million admissions DRG 
127 
• >2 million secondary 
diagnosis admissions 
• Avg LOS 5.6-8 days 
• >15 million office visits 
• Estimated direct and 
indirect cost of HF in the 
US for 2010:  $39.2 billion 
AHA Heart Disease, 2012 
2010 HF Definition 
• Syndrome caused by cardiac dysfunction, due to myocardial 
dysfunction  
– Neurohormonal and circulatory abnormalities 
– Pulmonary and systemic venous congestion and/or inadequate 
peripheral delivery 
• Characteristic symptoms 
• Usually progressive 
– Can be stabilized and dysfunction and remodeling may improve 
 
Definition of Heart Failure 
Classification Ejection 
Fraction 
Description 
I. Heart Failure with 
Reduced Ejection Fraction 
(HFrEF) 
≤40% Also referred to as systolic HF. Randomized clinical trials have 
mainly enrolled patients with HFrEF and it is only in these patients 
that efficacious therapies have been demonstrated to date. 
II. Heart Failure with 
Preserved Ejection 
Fraction (HFpEF) 
≥50% Also referred to as diastolic HF. Several different criteria have been 
used to further define HFpEF. The diagnosis of HFpEF is 
challenging because it is largely one of excluding other potential 
noncardiac causes of symptoms suggestive of HF. To date, 
efficacious therapies have not been identified.  
a. HFpEF, Borderline  41% to 49% These patients fall into a borderline or intermediate group. Their 
characteristics, treatment patterns, and outcomes appear similar to 
those of patient with HFpEF. 
b. HFpEF, Improved  >40%  It has been recognized that a subset of patients with HFpEF 
previously had HFrEF. These patients with improvement or recovery 
in EF may be clinically distinct from those with persistently 
preserved or reduced EF. Further research is needed to better 
characterize these patients.   Yancy et al. 2013 
Systolic and Diastolic Heart Failure 
Causes of Heart Failure 
• CAD 
• Valve disease 
• Hypertension 
• Congenital 
• Toxic 
• Cardiomyopathy 
• Infection 
• Myocarditis 
 
Types of Cardiomyopathy 
• Cardiomyopathy-- impairment in heart function with pump 
failure and associated with ventricular dilatation and 
hypertrophy 
 
• Primary cardiomyopathies  
– Genetic: hypertrophic, arrhythmogenic RV dysplasia, LV non-
compaction 
– Mixed: dilated, restrictive 
– Acquired: myocarditis, stress (takotsubo), peripartum, tachycardia 
induced CM 
• Secondary cardiomyopathies 
– Infiltrative (amyloidosis), hemachromatosis, toxicity (drugs, ETOH, 
chemotherapy), inflammatory (sarcoidosis, DM, hyperthyroidism, 
muscular dystrophy, autoimmune (lupus, scleroderma)  
Dilated CM (DCM) 
• Global enlargement 
• Decreased pumping function 
• EF< 40% 
• Systolic dysfunction 
Hypertrophic CM 
• LV hypertrophy  
– early systolic 
– diastolic dysfunction 
• Usually due to congenital defect 
– Most common 1:500 (AHA) 
• Obstructive or non-obstructive 
– “IHSS”, “HOCM” 
• SCD requiring ICD 
 
Restrictive CM 
• Least common CM 
• Filling defects 
– Diastolic dysfunction 
• Ventricle walls:  
– May thicken 
– Become stiff/rigid 
– Unable to relax 
 
 
• Primary 
– Idiopathic 
– Loeffler’s CM 
– Endomyocardial 
fibrosis 
• Secondary 
– Infiltrative 
• Amyloidosis 
• Sarcoidosis 
• S/p radiation 
– Storage 
• Hemochromatosis 
• Glycogen storage 
disease 
 
HF Pathophysiology 
• Heart Failure results in: 
– Increased cardiac workload 
– Decreased cardiac output 
• Activation of compensatory mechanisms in an 
attempt to maintain normal cardiac pumping 
function 
– Hemodynamic changes 
– Neurohormonal response 
– Ventricular remodeling 
Hemodynamic changes 
• Frank-Starling law of the heart 
– Increased preload=increased contractility 
– Initially is a compensatory mechanism 
• Normal ventricle can adjust  
• Failing ventricle loses compensatory ability 
and cardiac output decreases 
• Result: Pulmonary and systemic congestion 
Neurohormonal Activation 
Neurohormonal Response 
Detrimental Long Term 
Consequences 
LV 
remodeling 
and cell 
hypertrophy 
Increased 
heart rate 
Vaso-
constriction 
Sodium and 
water 
retention 
Cardiac cell 
death 
(apoptosis) 
Increased 
thirst 
Cardiac 
Cachexia 
So now what….. 
Goals of the Assessment of New Heart 
Failure 
• Define symptoms, signs, and their severity 
• Identify structural and functional abnormalities 
• Determine etiology of HF if possible 
• Evaluate risk for life-threatening arrhythmia  
• Quantify the degree of functional limitation 
imposed by HF 
• Guide therapy and tailor to individual goals of care 
 
 
Steps in Evaluation of New HF 
• History  
• Physical Exam 
• Diagnostic Labs and Tests 
• Determine need for specialists 
• Determine appropriate interval for f/u 
The History is a Goldmine 
• Define patient’s presentation 
• Assess clinical severity of symptoms 
• Seek clues to etiology 
• Identify exacerbating factors for HF 
• Identify comorbidities  
• Identify barriers to adherence  
 
Three common HF presentations 
• Decreased effort/exercise tolerance 
– Dyspnea, fatigue 
– May be mistakenly attributed to aging, deconditioning, or 
other medical disorders 
• Fluid retention 
– Leg, abdominal swelling reason for seeking attention 
– Other symptoms may be subtle 
• Incidental finding 
– No symptoms 
– Symptoms of another cardiac or noncardiac disorder 
– Abnormal test 
 
Symptoms Suggestive of HF 
Symptom History 
• Which HF sx predominate? 
• Duration of symptoms 
• Symptoms/illness that preceded HF 
• Define current limitations 
Medication History 
• Current medication regimen  
• Past medications  
• OTC medications or herbals, now or ever 
• NSAIDs  
• Weight loss medications 
• Chemotherapy 
 
Social History 
• Identify behaviors that could worsen HF 
– Substance use, diet history, noncompliance 
 
• Identify barriers to adherence 
– Behavioral 
– Socioeconomic  
– Cognitive/learning 
– Medical literacy 
– Cultural differences/Health beliefs 
Family History 
• Explore at least three generations, and 
children 
• Cardiovascular diseases, diagnosed or 
undiagnosed 
• Sudden death and Sudden cardiac death 
• Patient’s history will target more questions 
• Noncardiac familial diseases matter 
Comorbid Medical Conditions 
• Allergies  
• Other cardiovascular diseases, or symptoms of 
them 
• Other medical conditions, ever 
• Surgeries 
• XRT 
 
Physical Exam 
(ACC/AHA Class I) 
• Routine vital signs 
• Orthostatics 
• Weight 
• Height 
• Calculate BMI 
Assessment for Signs of HF 
J Cardiac Failure Vol 16, No 6 2010 
Other pertinent physical findings 
• Thyroid abnormalities 
• Lymphadenopathy 
• Cachexia 
• Jaundice 
• Liver or spleen enlargement 
• Signs of connective tissue disease 
• Slow mentation 
• Observation of respiration pattern 
 
Diagnostic Labs and Tests 
• Evaluate for reversible causes of HF 
• Evaluate for exacerbating conditions 
• Evaluate for comorbid conditions 
• Suggest severity of heart failure 
Diagnostic Labs  
(ACC/AHA Class I) 
• CBC, Electrolytes, BUN, Creatinine 
• Urinalysis 
• Fasting blood glucose, HbA1C 
• Fasting lipid profile 
• Liver function tests 
• TSH 
Diagnostic Labs  
(ACC/AHA Class IIa) 
• Ferritin (Hemachromatosis) 
• HIV 
• ANA (rheumatologic diseases) 
• SPEP/UPEP (amyloidosis) 
• Metanephrines (pheochromocytoma) 
• BNP or nt-proBNP 
• Viral Serologies 
• Genetic Testing 
 
* Other labs directed by clinical suspicion 
Diagnostic Tests 
(ACC/AHA Class I) 
• EKG 
– Arrhythmia, BBB, atrial 
abnormalities 
 
• PA/Lat CXR 
– Cardiomegaly, edema, congestion, 
effusions, enlarged PA 
Diagnostic Tests 
• Assessment of LVEF (Class I) 
– Echocardiogram 
– Radionuclide study 
– Cardiac MRI 
• Screen for cardiac ischemia (Class I) 
– History/physical 
• Angina or atypical chest pain 
• Claudication or physical signs of peripheral vascular disease 
– Noninvasive (IIb) 
• HF with LV dysfunction and no CP/ischemia) 
• Radionuclide study 
• Cardiac CTA 
– Invasive 
• Angiogram 
• Assess for sleep disordered breathing (Class IIa) 
• Wearable rhythm monitor (Class IIb) 
 
2D Echocardiogram with Doppler 
• Everyone (Class I) 
• No contraindications! 
• Assess LVEF, cardiac 
chamber sizes, wall 
thickness, wall motion, 
diastolic function, valves 
• Marginal at assessing RV 
size and function 
Cardiac Catheterization 
• Coronary Angiogram 
– HF + angina/ischemia (I) 
– HF + chest pain (IIa) 
– HF + known/suspected CAD (IIa) 
 
• Right Heart Cath 
– Right/left filling pressures 
– Cardiac output 
– Pulmonary arterial pressure 
 
• Other studies as indicated 
– Valve studies 
– Shunt studies 
– Evaluation for 
constriction/restriction 
Cardiac MRI 
• Delineates structure 
– Myocardium, pericardium, 
valves, chamber sizes, other 
intra/extracardiac structures 
• Precise LV/RV function  
• Wall motion  
• Viability, inflammation, 
infiltration, and scar 
• Characterize cardiomopathy 
• Contraindications: 
– Indwelling ferromagnetic 
material 
– GFR<30 (gadolineum) 
Endomyocardial Biopsy 
• Should be done in a center 
with expertise in 
technique and tissue 
handling/interpretation 
 
• Technique: 
– RIJ or Femoral Vein 
– Flexible bioptome 
– 5-10 samples from RV 
septum 
 
Classification of HF Severity 
• Clinical course 
• Diagnostic information 
• ACC/AHA HF staging system 
• Risk scoring systems 
• NYHA functional classification 
• Objective assessment of functional status 
– 6-Minute Walk Test 
– Cardiopulmonary Exercise Test 
 
 
Staging of Heart Failure 
End 
Stage HF 
Marked Sx at rest 
Max Med Tx 
Symptomatic HF 
Structural Heart Disease 
SOB, Fatigue 
Exercise Intolerance 
Asymptomatic HF 
LV Systolic Dysfunction 
Previous MI 
Asymptomatic Valvular Disease  
 
High Risk for Developing HF 
HTN, CAD, DM 
Family History of Cardiomyopathy 
 
A 
B 
C 
D 
NYHA Functional Classification 
• I: No limitation 
• II: Mild symptoms, slight limitation with activity 
• III: Marked symptoms and limitations with activity 
• IV: Symptoms at rest 
 
Cardiopulmonary Exercise Test (CPET, 
CMET, or CPX)  
(ACC/AHA Class IIa) 
• Defines interaction of heart, 
lungs, cell metabolism, and 
circulation 
• Gives functional and prognostic 
information 
• Indications 
– Determine contribution of HF to 
exercise limitation 
– Identify high risk patients who are 
candidates for advanced cardiac 
therapies 
Prognostic Value of CPX: Peak Oxygen 
Consumption 
P<0.002 for pVO2<14 vs. >14 
VO2>14 ml/kg/min 
VO2<14 
ml/kg/min 
(not 
listed) 
VO2<14 
ml/kg/min 
(listed) 
Heart Failure Risk Scoring Systems 
• Heart Failure Survival Score 
 
 
 
• Seattle Heart Failure Model 
http://meded.ucsd.edu/clinicalmed/heart.htm 
Markers of Poor Prognosis 
European Heart Journal.  2008; 29 (19): 2388-2442 
Your Assessment Will Guide The 
Therapy 
Standard Treatment 
 
• Pharmacologic therapy 
• Non-pharmacologic therapy 
• Device therapy 
Treatment Goals 
• Improve survival 
• Improve QOL 
• Improve, recognize and manage sx 
• Avoid precipitating factors 
• Decrease hospital stays 
 
 
 
 Pharmacological Therapy 
 ACE Inhibitors or Angiotensin Receptor 
Blockers (ARB’s) 
 Beta-blockers 
 Diuretics for volume 
 Digoxin 
 Aldosterone antagonists 
 Additional vasodilators 
 
ACE-Inhibitors 
• High risk and LVEF<40% with symptoms or not 
• Blocks Angiotensin I from converting to angiotensin II 
• Start small doses and titrate when euvolemic to wet 
 
• Reduce total mortality rate by 23% 
• Lower risk of death and lower risk for hospitalization for HF 
 
• Side effects: 
– Cough—dry, hacky,  related to bradykinin not broken down by angiotensin II 
– Angioedema 
– Hyperkalemia– less angiotensin II less aldosterone 
– Hypotension 
– Renal insufficiency 
• Contraindications 
– Pregnancy  
– Cr > 3.0 
– Renal stenosis 
– Hyperkalemia 
 
Guidelines: ARB 
• Alternative to ACE-I 
• Cough less common 
– Angiotensin II forms and breaks down bradykinin 
then blocked at the receptor 
• If not tolerated: Nitrate/Hydralazine 
combination 
Guidelines: β-blocker  
• High risk post MI, LVEF </= 40% with symptoms, 
asymptomatic (expert opinion)  
• Block sympathetic response 
• Reverse cardiac remodeling 
• Improve EF 
• Reduce all cause mortality by ~32% 
 
 
• Start when euvolemic on stable dose of ACE-I and diuretics 
• Start low and increase every 2 weeks 
• Monitor HR and BP 
• Monitor daily weigh and signs of congestion 
 
β-blockers 
• Caution 
– Diabetes with recurrent hypoglycemia  
– HR <55-60/min, second or third degree HB 
– Hypotension, SPB < 80-5mm Hg 
• Avoid 
– Asthma with active bronchospasm 
– Initiation/dose increase when fluid overloaded 
– Abrupt discontinuation , reflex tachycardia 
 
Guidelines: Aldosterone Antagonists 
• Functional class III-IV symptoms 
– On maximal HF therapy 
• Side effects 
– Hyperkalemia 
– Impotence/ menstrual changes  
– Gynecomastia 
• Eplerenone: more aldosterone selective 
• Contraindicated  
– Cr> 2.5 (or >2 in women) 
– K> 5.0 
• Check K and renal function at 3 days or 1 week, 
monthly x3 and q 3mo 
 
 
 
Other HF meds….. 
• Additional vasodilators 
– Hydralazine 
• Initial 37.5 qid, target 75mg qid 
– Isosorbide dinitrate 
• Initial 20mg qid, target 40mg qid  
• Digoxin: Aim for level < 1.0, interaction with 
Amiodarone 
• Statins: decrease LDL 
• Anticoagulation: Afib or thrombus 
• Antiarrhymthics: Amioardone and dofetilide 
 
 
What about Diuretics….. 
 
Diuretics 
Diuretic Dosage 
(mg/day) 
Onset of Action Action Duration Peak Oral 
Effect 
(Hours) 
Comments 
Oral  
(Hours) 
IV 
(Minutes) 
Oral 
(Hours) 
IV (Hours) 
Ascending  Loop of Henle 
Furosemide 40-400 1 5 6 2-3 1-3   
Bumetanide 1-5 0.5 5 6 2-3 1-3   
Torsemide 10-200 1 10 6-8 6-8 1-3   
Early Distal Tubule 
Metolazone 2.5-20 1 — 12-24 — 2-4 High potential 
for K+ loss  
Hydrochlorothiazide 25-100 2 — 12 — 4 Ineffective if 
GFR <30 
Chlorothiazide 500-1000 1 15-30 8 — 4 Ineffective if 
GFR <30 
Mann, D. Heart Failure 2nd ed. 2011  
Diuretic Risks 
• Hypokalemia 
– Arrhythmia 
– Muscle aches 
• Bicarbonate reabsorption metabolic alkalosis 
• Decreased serum uric acid excretion gout  
• Hyponatremia 
• Further neurohormonal activation 
• Stop diuretics when possible…….  
Consider Admission for….. 
• Signs and symptoms of pulmonary or systemic congestion 
– Even in the absence of weight gain 
• Major electrolyte disturbance 
• Associated comorbid conditions 
• Pneumonia 
• Pulmonary embolus 
• Diabetic ketoacidosis 
• Symptoms suggestive of transient ischemic accident or 
stroke 
• Repeated ICD firings 
• Previously undiagnosed HF with signs and symptoms of 
systemic or pulmonary congestion 
Advanced HF Therapy  
• Inotropes 
• Implantable Cardiac Defibrillators 
• Bi-ventricular pacemakers 
• Left Ventricular Assist Devices 
• Cardiac Transplant 
• Investigational medicine and devices 
• Palliative medicine consult/hospice at EOL 
 
Inotropic Therapy 
• Milrinone or Dobutamine 
– Routine scheduled infusions 
• Evidence does not support efficacy 
– Continuous infusions 
• Can lead to increased mortality 
  (Hunt et al., 2005) 
• Medicare requirements 
– Failure of maximum oral therapy  
– 20% improvement of cardiac index or wedge pressure 
– Symptoms at rest 
– Completion of Medicare form 
  (Option Care, 2005) 
  
 
Balancing the Effects of 
Inotropes 
• Benefits 
– Increase cardiac contractility 
– Dilate peripheral vasculature 
– Increase C.O. and C.I. 
 
 
• Negative Side Effects 
– ↑ myocardial O2 consumption 
– Hypotension 
– Tachycardia 
– Arrhythmias 
– Worsening HF 
 
 
Device Therapy- Rhythm Support
  
• Pacemakers 
– For bradyarrhythmias or after ablation 
• Implantable Cardiac Defibrillators 
– Reduces mortality in both ischemic and non-ischemic patients 
• Bi-ventricular pacemakers or defibrillators 
– Reduced mortality compared to medical management 
– Improves functional class, 6-minute walking distance, quality of 
life, maximum oxygen consumption, exercise time, ejection 
fraction, and LV diastolic and systolic diameters after 6 months 
 (Wilkoff, 2005)  
 
HF Disease Trajectory 
Goodlin SJ,. J Card Fail. 2004;10(3). 
Non-pharmacologic Therapy 
• Patient education 
• Home monitoring 
• Symptom management 
• Dietary 
• Lifestyle modifications 
• Exercise 
 
General Education 
• Psychological responses 
– Depression and anxiety common 
– Treatment is necessary if persists 
• Immunizations needed  
– Flu and pneumococcal vaccines 
• Prognosis 
• Goals of care: early and repeated 
• Advanced directives 
Conclusions 
• HF remains a leading cause of morbidity and 
mortality. 
• Multiple etiologies but all lead to neurohormonal 
activation.  Therapies are aimed at the etiology of HF 
and the modulation of the neurohormonal axis. 
• Treatment goals are individualized and can 
incorporate pharmacologic, surgical, mechanical 
options. 
• Goals of care and advanced directives are key 
interventions. 
 
